Shanghai



Shanghai is a crucial gateway to China’s dynamic economy. From our Shanghai office, we help U.S. and European Union companies navigate the Chinese market and Chinese businesses expand in the United States and around the world.

Additionally, we provide space in our office for ChinaSF, a collaborative public/private economic development initiative that is operated by the San Francisco Center for Economic Development and the City of San Francisco, with the financial and strategic backing of key international business leaders. ChinaSF works to foster trade and economic development between San Francisco and China.

NOTE: Nixon Peabody LLP is a limited liability partnership organized and registered under the laws of the State of New York. A list of the names of the partners and their professional qualifications is open to inspection at any of its offices. Lawyers in our Shanghai office are not licensed as local lawyers in the People’s Republic of China.

Deal Watch: Private equity hits new heights

The American Lawyer | November 22, 2021

This article on the surge in private equity deals includes NP for advising the owners of skin care brand Obagi in its $1.2 billion business combination agreement with Waldencast Acquisition Corp. and the spinoff of Obagi’s operations in China.

The NP team was led by David Cheng, chair and managing partner of the firm's China and Asia-Pacific practice, and New York City Corporate partners Michael Smith and Richard Langan. The team that advised Obagi also included Chicago Corporate partner David Brown, Rochester Corporate partner Jeremy Wolk, Washington, DC Complex Commercial Disputes partner and Antitrust team leader Gordon Lang, and Washington, DC Corporate senior counsel Kenneth Silverberg. Other members of the team included Boston Corporate associate Anthony Bova and Chinese legal consultant Kelly Xiang.

Four firms lead three-way SPAC to create new beauty platform

Bloomberg Law | November 18, 2021

This article covering a roughly $1.2 billion merger of skin care and beauty brands with a special purpose acquisition company mentions NP for advising the owners of skin care brand Obagi in its business combination agreement with Waldencast Acquisition Corp. and the spinoff of Obagi's operations in China.

The NP team was led by David Cheng, chair and managing partner of the firm's China and Asia-Pacific practice, and New York City Corporate partners Michael Smith and Richard Langan. The team that advised Obagi also included Chicago Corporate partner David Brown, Rochester Corporate partner Jeremy Wolk, Washington, DC Complex Commercial Disputes partner and Antitrust team leader Gordon Lang, and Washington, DC Corporate senior counsel Kenneth Silverberg. Other members of the team included Boston Corporate associate Anthony Bova and Chinese legal consultant Kelly Xiang.

After the turbulent Trump years ,what will it take for the U.S. and China to reset their relationship?

San Francisco Business Times | February 26, 2021

This article covers a recent “Bridge from China“ event, sponsored by NP, that included discussion of how the pandemic has affected cross-border business, geopolitical tensions of recent years, and what the administration change could mean for U.S. businesses wanting to do business in China. David Cheng, chair and managing partner of NP’s China & Asia Pacific practice, served as a panelist and David Kaufman, director of Global Strategies, co-moderated the panel discussion.

Location

Li Tong Plaza, Suite 2301

1350 North Sichuan Road

Shanghai 200080

China

Phone: +86 21 6137 5500

Fax: +86 21 6137 5588

Back to top